grant
Nocturnal hypoxemia dysregulates skeletal muscle protein homeostasis in COPD
Organization CLEVELAND CLINIC LERNER COM-CWRULocation CLEVELAND, UNITED STATESPosted 1 Jan 2025Deadline 31 Dec 2029
NIHUS FederalResearch GrantFY2025AssayAutoregulationAwardBioassayBiological AssayBiologyBody TissuesCOPDCause of DeathCell BodyCell LineCell modelCellLineCellsCellular modelChronic Obstruction Pulmonary DiseaseChronic Obstructive Lung DiseaseChronic Obstructive Pulmonary DiseaseClinicClinical EvaluationClinical TestingDNA Molecular BiologyDataDevelopmentDiameterExposure toFundingGastrocnemius MuscleGene TargetingGeneticGoalsGrip strengthHIF 1 alphaHIF-1alphaHIF1-AlphaHIF1AHIF1A geneHIF1αHand StrengthHomeostasisHumanHypoxemiaHypoxiaHypoxia Inducible FactorHypoxicIn VitroInstitutionInterstitial Lung DiseasesKnowledgeLaboratoriesLeadLegLungLung DiseasesLung Respiratory SystemMOP1MeasuresMediatingMediatorMentorsMentorshipMetabolic PathwayMiceMice MammalsModelingModern ManMolecularMolecular BiologyMorbidityMorbidity - disease rateMurineMusMuscleMuscle AtrophyMuscle FibersMuscle TissueMuscle functionMuscular AtrophyMyotubesO elementO2 elementObservation researchObservation studyObservational StudyObservational researchOxygenOxygen DeficiencyPatient CarePatient Care DeliveryPatientsPb elementPhenylalaninePhysiciansPhysiological HomeostasisProductivityProgram DevelopmentProtein BiosynthesisProtein Synthesis InhibitionProteinsPublishingPulmonary DiseasesPulmonary DisorderPulmonary HypertensionPuromicinaPuromycinPuromycinePuromycinumResearchResearch InstituteRhabdomyocyteRibosomal Peptide BiosynthesisRibosomal Protein BiosynthesisRibosomal Protein SynthesisRoleScientific Advances and AccomplishmentsScientistSignal PathwaySkeletal FiberSkeletal MuscleSkeletal Muscle CellSkeletal Muscle FiberSkeletal MyocytesSleepStrains Cell LinesStructureSystemTissuesTranslational ResearchTranslational ScienceUnited StatesVoluntary MuscleWild Type MouseWorkawakebarrier to carebarrier to health carebarrier to treatmentcare for patientscare of patientscareercareer developmentcaring for patientschronic obstructive pulmonary disorderclinical relevanceclinical significanceclinical testclinically relevantclinically significantcompare to controlcomparison controlcultured cell linedevelopmentaldisease of the lungdisorder of the lungeffective therapyeffective treatmentexperienceextensor digitorumgastrocnemiusheavy metal Pbheavy metal leadhuman modelhypoxemicin vitro testingin vivoinnovateinnovationinnovativeintervention designlung disordermodel of humanmortalitymouse modelmurine modelmuscle breakdownmuscle bulkmuscle degradationmuscle deteriorationmuscle formmuscle lossmuscle massmuscle wastingmuscularnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnocturnal Hypoxemianormoxianovelnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetobstacle to careobstacle to health carepharmacologicpre-clinicalpreclinicalprogramsprotein homeostasisprotein synthesisproteostasisresearch clinical testingresponsesarcopeniasarcopenicscientific accomplishmentsscientific advancesskeletal muscle atrophyskeletal muscle breakdownskeletal muscle lossskeletal muscle protein lossskeletal muscle wastingsocial roletargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapy designtranslation researchtranslational investigationtreatment designwildtype mouse
Description preview
Chronic obstructive pulmonary disease (COPD) is the 4th most common cause of death in the United States.
Sarcopenia, or skeletal muscle loss, impacts up to 40% of COPD patients and is a major cause of morbidity
and mortality. Despite the high significance, there are currently no effective therapies for sarcopenia in COPD
due to limited…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click